Product details
Background：Talacotuzumab (TAL, JNJ-56022473) is an IgG1 monoclonal antibody targeting CD123 preferentially via antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells and has been shown to induce potent in vitro ADCC against IL3RA-expressing AML blasts/LSC and to reduce leukemic cell growth in murine xenograft models of human AML. In addition, the antibody inhibits signaling by IL-3, the main ligand of CD123, to reduce the proliferation of leukemic progenitor cells.
• CD123 and its potential clinical application in leukemias., PMID:25445480
• Interleukin-3 receptor in acute leukemia., PMID:14671644
• IL-3R-alpha blockade inhibits tumor endothelial cell-derived extracellular vesicle (EV)-mediated vessel formation by targeting the β-catenin pathway., PMID:29238040
• The role of interleukin-3 in classical Hodgkin’s disease., PMID:15621820
• IL-3 Decreases Cartilage Degeneration by Downregulating Matrix Metalloproteinases and Reduces Joint Destruction in Osteoarthritic Mice., PMID:27183574
• New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells., PMID:17667524
• Receptor cross-linking on human plasmacytoid dendritic cells leads to the regulation of IFN-alpha production., PMID:17056507
• AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells., PMID:25879549
• Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice., PMID:16882709
• SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia., PMID:24942980
